WEPREDIC
WEPREDIC is a French biotech group providing proprietary in vitro liver cell models (HepaRG®, HepaSH™), chemical probes, and safety/bioavailability assessment services for pharmaceutical, cosmetics, and industrial compound manufacturers, serving clients including Sephora, Pierre Fabre, and Yves Rocher.
- Company typePrivate
- Founded1990
- HeadquartersSaint-grégoire, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What WEPREDIC does
WEPREDIC is a privately held French biotech group headquartered in Saint-Grégoire (Rennes metropolitan area), operating since the 1990s through multiple entities: Wepredic SARL (parent), Biopredic International SARL (assay manufacturing), Eurosafe (safety and bioavailability assessment services), Starlight (smart chemical probe synthesis), and Biopredic Inc. The group provides chemo-biological models and in vitro testing solutions for assessing the fate and safety of drugs, cosmetics, and industrial compounds, serving pharmaceutical companies, cosmetics manufacturers (named logos include Sephora, Nuxe, Pierre Fabre, and Yves Rocher), industrial chemical producers, and academic research institutions.
The core technology platform centers on two proprietary human liver cell models — HepaRG® (an established human hepatoma cell line used for drug metabolism, CYP induction, hepatotoxicity, steatosis, cholestasis, genotoxicity, and virology studies) and HepaSH™ (experimental human hepatocytes with lower inter-individual variation than primary human hepatocytes, used for cholestatic DILI prediction and hepatic clearance studies). These cell models anchor a broader catalog of transporter substrates and inhibitors (OCT1, OATP1B3, OAT1/2, OCT, MRP2/Pgp), fluorescent probes (Fluobile bile canaliculi probes, Fluoalb™ albumin probes), and assay reagents organized across DMPK, genotoxicity, hepatotoxicity, CYP P450, and non-genotoxic carcinogen categories. The cell lines have been continuously validated through a scientific publication record dating to 2006.
WEPREDIC generates revenue through three complementary streams: (1) one-time product sales of biochemical reagents and cell models via a direct e-commerce storefront at unit prices typically ranging from €45–€95, (2) contract safety and bioavailability assessment services delivered through Eurosafe (including volunteer studies for cosmetic testing), and (3) biological assay system sales through Biopredic. The go-to-market combines direct e-commerce for catalog products, sales-led engagement for services (phone + contact form), and event-driven outreach through participation in toxicology conferences such as SOT and SSX India. Distribution is global via the e-commerce channel and includes active geographic expansion efforts into Japan (Tokyo Metropolitan Government engagement, Feb 2026) alongside continued EMEA operations.
WEPREDIC firmographics
Firmographics- Name
- WEPREDIC
- Legal name
- Wepredic SARL
- Website
- https://wepredic.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- WEPREDIC is a French biotech group providing proprietary in vitro liver cell models (HepaRG®, HepaSH™), chemical probes, and safety/bioavailability assessment services for pharmaceutical, cosmetics, and industrial compound manufacturers, serving clients including Sephora, Pierre Fabre, and Yves Rocher.
- Ownership category
- akta.pro rank
WEPREDIC industry classification
Industry- Product category
- Biotechnology Research Products
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Pathology & Histopathology Services (HLAGAFAI)
Keywords
Where WEPREDIC is headquartered
LocationHeadquarters
- HQ city
- Saint-grégoire
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
WEPREDIC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Sales: Sale of biochemical compounds including transporter inhibitors, substrates, reference standards, cell culture products, and fluorescent probes through e-commerce platform. Products priced per unit (e.g., €45-95 per item).
- Safety & Bioavailability Assessment Services (Eurosafe): Contract research services for safety assessment and bioavailability testing, including studies on volunteers for cosmetic testing.
- Assay Systems (Biopredic): Manufacture and sale of biological assay systems for drug discovery and toxicology research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Reference compounds sold as single units |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
WEPREDIC product offering
Product offeringCore offering
WEPREDIC is a French biotech group that develops, manufactures, and sells proprietary human liver cell models (HepaRG® and HepaSH™), reference compounds (transporter substrates/inhibitors), and fluorescent probes for in vitro safety testing. Through its Eurosafe subsidiary it delivers contract safety and bioavailability assessment services, and through Starlight it designs chemical probes — all targeted at pharmaceutical, cosmetics, and industrial compound customers seeking human-relevant, animal-free toxicology data.
Product overview
WEPREDIC is a French biotech group providing chemo-biological models for assessing the fate and safety of drugs, cosmetics, and industrial compounds. The group consists of three core operating subsidiaries: Biopredic International (which manufactures and markets assay systems), Eurosafe (which provides safety and bioavailability assessment services), and Starlight (which designs and synthesizes smart chemical probes). The portfolio includes two proprietary liver cell models — HepaRG® and HepaSH™ — which serve as the foundation for the company's in vitro testing solutions. These are complemented by a broad catalog of reference compounds (transporter substrates and inhibitors), fluorescent probes (Fluobile and Fluoalb™ lines), and assay reagents organized across DMPK, genotoxic, hepatotoxic, endocrine disruptor, CYP P450, and non-genotoxic carcinogen product categories. The group serves multinational cosmetics and pharmaceutical companies including Sephora, Nuxe, Pierre Fabre, and Yves Rocher.
Differentiator
Problem solved
Functional benefit
Brands
- Biopredic: Biological assay systems - manufactures and markets assay products including HepaRG cells and HepaSH hepatocytes
- Eurosafe
- Starlight
- HepaRG
- HepaSH
- Fluoalb
- Fluobile
Products and services
- Biopredic International Biological Assay Systems
- Eurosafe Safety & Bioavailability Assessment Services
Companies that use WEPREDIC
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
WEPREDIC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
WEPREDIC partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Tokyo Metropolitan GovernmentminorVisit by Tokyo Metropolitan Government representatives as part of ongoing collaborations with Japanese stakeholders. Discussion focused on expansion of Wepredic entities in Japan and contribution to Japanese market development in innovative in vitro technologies.
- Lebanese University (UL)coreEducational exchange partnership for New Approach Methodologies (NAMs) training using HepaRG cell model. Remote real-time training video sessions with more than 50 students attending. Focused on 2-D HepaRG cell culture basics and practical cell culture techniques.
- University of Applied Sciences and Arts Northwestern Switzerland (FHNW)coreCollaborative partner in NAMs educational exchange program. Contributed to interactive sessions on generating complex microtissues, data management, analysis, and visualization. More than 50 students attended from their School of Life Sciences.
- Edeilwess Connect GmbH (Edw)corePartner in NAMs training initiative providing expertise in data management, analysis, and visualization. Contributed to interactive sessions alongside university partners.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
WEPREDIC competitors and assessment
Company assessmentDirect peers
- Cyprotex (an Evotec company): Specialized CRO offering in vitro ADME/DMPK, hepatotoxicity, and transporter assay services. Direct overlap with Eurosafe's safety/bioavailability assessment services and Biopredic's DMPK/transporter product lines.
- BioIVT: Supplier of human biospecimens, primary hepatocytes, and ADME/toxicology research services. Comparable to WEPREDIC in supplying hepatic cell models and supporting in vitro safety and metabolism studies for pharma/cosmetics clients.
- Sekisui Xenotech: Provider of hepatic products (human hepatocytes), subcellular fractions, and ADME/DMPK services for drug safety assessment. Closely comparable to WEPREDIC on hepatic models and DMPK services.
Broad incumbents
- Thermo Fisher Scientific: Diversified life sciences tools leader with Gibco cell culture products, primary hepatocytes, and toxicology assay platforms. Overlaps with WEPREDIC on in vitro hepatic models and ADME reagents, though serves a much broader customer base.
- Corning Life Sciences: Major cell culture and life sciences tools supplier (e.g., HepatoSure hepatocytes, Matrigel). Comparable to Biopredic on cell-based assay and hepatic culture product lines.
- Inotiv: Contract research organization providing safety assessment, DMPK, and toxicology services across drug and chemical industries. Overlaps with Eurosafe's contract safety and bioavailability business on the services side.
- Lonza: Global contract development and manufacturing organization with a substantial cell biology and hepatic products portfolio (e.g., primary hepatocytes, HepatoSure). Highly relevant as a large incumbent competing in the same in vitro hepatic model and ADME/DMPK space as WEPREDIC, though much broader in scope.
- Eurofins Scientific: Global testing services group with a large cosmetics/personal care testing and in vitro safety assessment offering. Direct overlap with Eurosafe's cosmetic safety testing services for cosmetics clients like Sephora and Yves Rocher.
Emerging players
- Promega Corporation: Provider of cell-based assay reagents, luminescent/fluorescent probes, and ADME/toxicology kits. Comparable to Starlight's fluorescent probe products (Fluobile, Fluoalb) and Biopredic's assay reagent lines.
- Cellartis (Takara Bio): Developer of iPSC-derived hepatic cell models for drug discovery and toxicology. Adjacent emerging competitor to HepaRG/HepaSH, particularly as pharma clients shift toward iPSC-based alternatives for DILI and DMPK applications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
WEPREDIC social profiles
Digital presenceWEPREDIC financial estimates
Financial estimateRevenue estimate
Valuation estimate
WEPREDIC leadership team
Management profileNumber of profiles
Profiles1 record
WEPREDIC subsidiaries and ownership
Company hierarchySubsidiaries4 records
WEPREDIC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WEPREDIC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WEPREDIC
What does WEPREDIC do?
WEPREDIC is a French biotech group that develops, manufactures, and sells proprietary human liver cell models (HepaRG® and HepaSH™), reference compounds (transporter substrates/inhibitors), and fluorescent probes for in vitro safety testing. Through its Eurosafe subsidiary it delivers contract safety and bioavailability assessment services, and through Starlight it designs chemical probes — all targeted at pharmaceutical, cosmetics, and industrial compound customers seeking human-relevant, animal-free toxicology data.
Is WEPREDIC a public or private company?
WEPREDIC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was WEPREDIC founded?
WEPREDIC was founded in 1990. It employs 1 to 10 people.
Where is WEPREDIC based?
WEPREDIC is headquartered in Saint-grégoire, France, in the Europe region.
How does WEPREDIC make money?
Three revenue lines are on record. Product Sales are the primary driver. The others are safety & Bioavailability Assessment Services (Eurosafe) and assay Systems (Biopredic).
Who are WEPREDIC's main competitors?
Direct peers on record are Cyprotex (an Evotec company), BioIVT and Sekisui Xenotech. Broad incumbents are Thermo Fisher Scientific, Corning Life Sciences, Inotiv, Lonza and Eurofins Scientific. Emerging players are Promega Corporation and Cellartis (Takara Bio).
Does WEPREDIC have an API?
No public API is recorded for WEPREDIC.
What industry is WEPREDIC in?
WEPREDIC's product category is Biotechnology Research Products. Its primary akta.pro industry code is HLAGAFAI, Pathology & Histopathology Services. Its NAICS code is 541714 and its SIC code is 8734.